CLL Flashcards

1
Q

CLL Immunophenotype

A

CD5(+) + CD10-, CD19+, CD20 (dim), CD23(+) surface Ig (dim, bright expresses leukemic phase of another b cell neoplasm)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Mantle cell immunophenotype

A

CD5+ (like CLL, but CD23 negative)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Low risk cytogenetic features of CLL

A

1) Del 13q14
2) Trisomy 12 + del 11s22.3 (ATM)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

sequela of CLL

A

*Pure red cell aplasia
*secondary malignancies (eg nonmelanoma skin cancers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Indications for treatment in CLL

A

Evidence of progressive marrow failure (Hgb <10, plt count <100k and declining, and neutropenia) (IF stable cytopenia (eg. plt <100), doesn’t need treatment)
Massive (ie, ≥6 cm below the left costal margin) OR symptomatic splenomegaly (>6cm)
Massive (ie, ≥10 cm in longest diameter) OR symptomatic lymphadenopathy
Progressive lymphocytosis with an increase of >50 percent over a two-month period OR lymphocyte doubling time (LDT) of <6 months (**relative indication)
**
IF absolute count <30k, observe for longer period of time before starting treatment even if LDT <6 months
*Lymphocytosis alone is not a strict indication for treatment…
*exclude infection first (can have exaggerated lymphocyte response to infection)
Constitutional symptoms (Significant fatigue (ie, ECOG PS >2, inability to perform usual activities), Night sweats for ≥1 month without evidence of infection, Unintentional weight loss ≥10 percent within the previous six months, Fevers for ≥2 weeks without other evidence of infection – impacting quality of life
Treatment (eg. steroid) refractory autoimmune cytopenias,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

1) PI3k inhibitor SE’s 2) Required prophylaxis when using

A

1) pneumonitis, diarrhea, PNA
2) PJP ppx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Immunophenotypic marker that is adverse prognosticator in CLL

A

CD38+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ibrutinib most common SE

A

Hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

BTK inhibitor less likely to cause AF

A

Zanubrutinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PI3k SE’s

A

Itis’s (colitis, transaminitis, pneumonitis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Other commonly tested cause of anemia in CLL

A

PRCA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PRCA clinical features

A

isolated anemia w/ reticulocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

CD20 expression in CLL

A

*Dim

How well did you know this?
1
Not at all
2
3
4
5
Perfectly